Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12.
Lancet. 2023.
PMID: 37321235
Free PMC article.
Clinical Trial.
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS.
Firbas C, et al. Among authors: buerger v.
Vaccine. 2006 May 15;24(20):4343-53. doi: 10.1016/j.vaccine.2006.03.009. Epub 2006 Mar 20.
Vaccine. 2006.
PMID: 16581161
Clinical Trial.
Item in Clipboard
Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.
Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS.
Firbas C, et al. Among authors: buerger v.
Vaccine. 2010 Mar 11;28(12):2397-407. doi: 10.1016/j.vaccine.2009.12.072. Epub 2010 Jan 9.
Vaccine. 2010.
PMID: 20060945
Clinical Trial.
Item in Clipboard
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP.
Klade CS, et al. Among authors: buerger v.
Gastroenterology. 2008 May;134(5):1385-95. doi: 10.1053/j.gastro.2008.02.058. Epub 2008 Mar 4.
Gastroenterology. 2008.
PMID: 18471515
Clinical Trial.
Item in Clipboard
Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C.
Dubischar-Kastner K, et al. Among authors: buerger v.
Vaccine. 2010 Jul 19;28(32):5197-202. doi: 10.1016/j.vaccine.2010.05.069. Epub 2010 Jun 10.
Vaccine. 2010.
PMID: 20541581
Clinical Trial.
Item in Clipboard
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.
McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A, Kosulin K, Koren M, Mader R, Zoihsl O, Wressnigg N, Dubischar K, Buerger V, Eder-Lingelbach S, Jaramillo JC.
McMahon R, et al. Among authors: buerger v.
J Travel Med. 2024 Mar 1;31(2):taad156. doi: 10.1093/jtm/taad156.
J Travel Med. 2024.
PMID: 38091981
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite